4.0 Article

A Leaking-Proof Theranostic Nanoplatform for Tumor-Targeted and Dual-Modality Imaging-Guided Photodynamic Therapy

Journal

BME FRONTIERS
Volume 4, Issue -, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.34133/bmef.0015

Keywords

-

Ask authors/readers for more resources

This study designed a protein-based leaking-proof theranostic nanoplatform for dual-modality imaging-guided tumor photodynamic therapy. By conjugating chlorin e6 (Ce6) to ferrimagnetic ferritin (MFtn), a biomineralized ferrimagnetic core was generated in the cavity of ferritin, resulting in the formation of a fluorescent ferrimagnetic ferritin nanoplatform (MFtn-Ce6). The distribution and tumor targeting of MFtn-Ce6 can be detected by magnetic resonance imaging and fluorescence imaging. The results showed that MFtn-Ce6 exhibited effective dual-modality imaging and enhanced tumor accumulation and retention of photosensitizer, providing precise tracking and optimal treatment time window for PDT. The co-localization of ferritin and the iron oxide core confirmed the high stability of the nanoplatform in vivo. Mice treated with MFtn-Ce6 demonstrated significant tumor-suppressive activity after laser irradiation.
Objective: A protein-based leaking-proof theranostic nanoplatform for dual-modality imaging-guided tumor photodynamic therapy (PDT) has been designed. Impact Statement: A site-specific conjugation of chlorin e6 (Ce6) to ferrimagnetic ferritin (MFtn-Ce6) has been constructed to address the challenge of unexpected leakage that often occurs during small-molecule drug delivery. Introduction: PDT is one of the most promising approaches for tumor treatment, while a delivery system is typically required for hydrophobic photosensitizers. However, the nonspecific distribution and leakage of photosensitizers could lead to insufficient drug accumulation in tumor sites. Methods: An engineered ferritin was generated for site-specific conjugation of Ce6 to obtain a leaking-proof delivery system, and a ferrimagnetic core was biomineralized in the cavity of ferritin, resulting in a fluorescent ferrimagnetic ferritin nanoplatform (MFtn-Ce6). The distribution and tumor targeting of MFtn-Ce6 can be detected by magnetic resonance imaging (MRI) and fluorescence imaging (FLI). Results: MFtn-Ce6 showed effective dual-modality MRI and FLI. A prolonged in vivo circulation and increased tumor accumulation and retention of photosensitizer was observed. The time-dependent distribution of MFtn-Ce6 can be precisely tracked in real time to find the optimal time window for PDT treatment. The colocalization of ferritin and the iron oxide core confirms the high stability of the nanoplatform in vivo. The results showed that mice treated with MFtn-Ce6 exhibited marked tumor-suppressive activity after laser irradiation. Conclusion: The ferritin-based leaking-proof nanoplatform can be used for the efficient delivery of the photosensitizer to achieve an enhanced therapeutic effect. This method established a general approach for the dual-modality imagingguided tumor delivery of PDT agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available